Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2032

Study Completion Date

December 1, 2033

Conditions
Neurofibromatosis 1Plexiform Neurofibroma
Interventions
DRUG

Cabozantinib Oral Tablet

"Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib."

DRUG

Selumetinib Oral Capsule

"Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events."

Trial Locations (1)

34294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Indiana University

OTHER

collaborator

United States Department of Defense

FED

lead

Girish Dhall, MD

OTHER